Asia-focused private equity firm DCP Capital has reached an agreement to spend about 1.94 billion yuan (over $283 million) for a 9 per cent stake in Tonghua Dongbao Pharmaceutical, a Shanghai-listed provider of insulin used in the treatment of diabetes.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
